Katie Tryhane
Stock Analyst at Credit Suisse
(1.97)
# 2,995
Out of 4,761 analysts
21
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $163.02 | +74.83% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $17.30 | +189.02% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $210.23 | +76.00% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $4.07 | +440.54% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $452.77 | +70.06% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $4.11 | +1,213.87% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $16.46 | +294.90% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $160.46 | +43.34% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $20.87 | +163.54% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $78.23 | -74.43% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $532.55 | -7.99% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $190.43 | +170.44% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $201.39 | +16.69% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $163.02
Upside: +74.83%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $17.30
Upside: +189.02%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $210.23
Upside: +76.00%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $4.07
Upside: +440.54%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $452.77
Upside: +70.06%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $4.11
Upside: +1,213.87%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $16.46
Upside: +294.90%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $160.46
Upside: +43.34%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $20.87
Upside: +163.54%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $78.23
Upside: -74.43%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $532.55
Upside: -7.99%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $190.43
Upside: +170.44%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $201.39
Upside: +16.69%